The purpose of this work was to estimate the degree of risk that might be associated with human exposure to low levels of the plasticizer di(2-ethylhexy1)phthalate (DEHP). DEHP is a common component, sometimes at high concentrations, of polyvinyl chloride (PVC) plastics and was recently reported by the National Toxicology Program (NTP) to be carcinogenic in rats and mice, inducing hepatocellular tumors in both species. This work was also designed to illustrate an approach to risk assessment that attempts to incorporate all available biological data. Based on the dose-response data generated by the NTP bioassays, we have performed extrapolations of risk to low dose levels using several procedures, including some that incorporate inferences from the available data that shed light on the likely relationship between dose level and risk at low dose levels. In drawing these inferences, consideration was given to such factors as genotoxicity, metabolism and pharmacokinetics, and physiological and biochemical effects of DEHP that might reveal its mechanism of action. The relative merits of each of the various risk estimates are described, based on current understanding of DEHP's mode of biological action. It is concluded that DEHP's mechanism of carcinogenicity in rodents most likely involves its ability to induce peroxisome proliferation and related enzymatic changes, although other mechanisms cannot be excluded. If humans and rodents are assumed to be at the same risk at the same daily dose level of DEHP, application of the various low dose extrapolation models leads to the prediction that the daily dose resulting in a lifetime risk of no more than 1 in 1 million would be between 1.5 and 791 mg/kg per day, with the most likely figure being 116 mg/kg per day. If the carcinogenicity of DEHP is dependent upon its pattern of metabolism, however, it would be inappropriate to extrapolate from rodents to man without qualification because of the major quantitative differences in metabolism in rats, mice, and primates, including man. One of the major differences in metabolism of DEHP between rats and mice and primates is in production of a metabolite whose level may be an indicator of the level of peroxisomal activity and, hence, if the peroxisome proliferation theory of DEHP carcinogenicity is correct, of carcinogenic risk. However, the substantial doubt that exists regarding the applicability of rodent carcinogenicity data to humans must be expressed in qualitative terms. MLCHAN I SM UNKNOWN L i f e t i m e r i s k p e r U n i t o f a v e r a g e . FIG. 2. Broad outline of carcinogenesis risk assessment.
INTRODUCTION
I(2-ETHYLHEXYL)PHTHALATE (DEHP), the structure Of which is shown in Figure 1 along with I> those of its two primary hydrolysis products, is a widely used plasticizer for polyvinyl chloride (PVC). It has been estimated that 1188 million pounds of plasticizers were used in PVC in 1980, and of this total, 30% (about 356 million pounds) was DEHP.'') PVC plastics may contain up to 40% DlEHP by weight and are widely used in consumer products, such as imitation leather bags and fur- RISK ASSESSMENT OF DEHP nishings, wallpaper, lawn furniture, rainwear, swimming pool liners, flooring, footwear, children's toys, containers and tubing for transfusions of blood and blood products.'') Since DEHP is not chemically bound within the PVC, there is at least the potential for widespread human exposure to DEHP as a result of migration out of the plastic. Human exposure to DEHP is of concern particularly in light of the recent report by the National Toxicology Program that DEHP at high dietary levels is carcinogenic in rats and mice.12) Estimation of the magnitude of human exposure to DEHP is, however, extremely complex because of the wide range of items that contain DEHP and the uncertainty regarding how much of the DEHP content of a PVC item to which someone was exposed would reach that individual and how much would be absorbed. No attempt has been made to estimate human exposure in this paper. Rather, our purpose is to describe the available data pertinent to the assessment of carcinogenic risk resulting from exposure to DEHP and to present estimates of risk per unit of dose (or no-observedeffect levels), which can subsequently be combined with estimates of human exposure to estimate human risk.
The conduct of this risk assessment follows the recommendations of the National Academy of Sciences.13) It starts with a critical review and evaluation of the literature pertaining to the carcinogenic properties of DEHP. This is followed by a review of data that might shed light on the underlying mechanism(s) of tumor induction in animals. This may assist in dealing with the next two components of risk assessment: dose-response evaluation and interspecies extrapolation. The approach to risk assessment used here is one in which several estimates are presented, along with a discussion of their relative degrees of support based on current understanding of DEHP's biological behavior. We avoid presenting only worst-case estimates but also attempt to avoid overstating the degree of certainty associated with the other estimates presented.
The broad outline of this risk assessment process is presented in Figure 2 . Each component of this process is discussed in relation to available data on DEHP.
dose male rats (P = 0.01). No other tumor type was significantly increased in incidence in rats.
In mice, there was a dose-related decrease in body weight gain in female mice from Week 25 to the end of the study, but food consumption was within 4% of the control level in both treated groups. No1 positive trends in mortaility were noted, but the low dose female mice had significantly shortened survival compared to controls. Overall, survival to the end of the study varied between 50% and 78Yo in the various groups. 'The incidence of liver tumors was increased in treated mice, as shown in Table 2 . By the Cochran-Armitage test, there was a significant dose-related trend in the incidence of hepatocellular carcinoma (P = 0.018) and combined carcinoma and adenoma (P = 0.002) in male mice and of the same tumor types in females (P I 0.001 for both). By direct comparison using Fisher's exact test there were significant increases in hepatocellular carcinoma in high dose male mice ( P = 0.022) and low dose ( P = 0.006) and high dose (P 5 0.001) females. Combined carcinoma and adenoma were significantly increased in all groups of mice fed DEHP (P = 0.013 in low dose males, P = 0.002 in high dose males, P = 0.001 in low dose females, and P 5 0.001 in high dose females). Of the 57 treated mice of both sexes having hepatocellular carcinoma, 20 (12 males and 8 females) had pulmonary metastases. None of the controls had pulmonary metastases. No other type of neoplasm was increased in incidence in treated mice of either sex. Northup et al.(lz) have suggested that the maximum tolerated dose (MTD) was exceeded in all treatment groups except low and high dose male mice and low dose female rats because body weight gain was depressed by more than 10% in all other treated groups. NTP,(z) however, have pointed out that the 10% weight differential is only a guideline and that the primary reason for not exceeding the theoretical MTD is to avoid excessive early deaths, which might prevent tumor development, and to avoid pathological changes other than neoplasia that might be involved in secondary mechanisms of carcinogenesis. NTP concluded that both of these goals were fulfilled in the case of the DEHP bioassay. However, as will be discussed in more detail later, there is support for the hypothesis that peroxisome proliferation, which occurs in rats and mice at the doses of DEHP used in the NTP bioassay, ('3.14) is involved in a secondary mechanism of cancer induction. At low doses where peroxisome proliferation does not occur, one would not expect cancer to develop.
In both mice and rats, only liver tumors were increased in incidence. The relevance of liver tumors in rodents to humans has been questioned, particularly because of the high and variable spontaneous incidence of liver tumors in various strains of m i~e ( '~. '~) and the high spontaneous incidence in the livers of rats of preneoplastic cells that can be stimulated by promoting agents to produce Such high incidences of preneoplastic cells are not known to exist in the human liver, which, therefore, would not be susceptible to enhancement of tumor incidence by such a mechanism.
Taking these factors into account is is concluded that under the conditions of the NTP bioassay, DEHP at very high dietary levels was carcihogenic to mice and rats of both sexes. There does, however, remain some question of the relevance of these findings to lower dose levels and to humans. This topic is discussed in detail in a later section.
Strength of evidence of carcinogenicity
As described above, the only evidence that DEHP is carcinogenic comes from the NTP bioassay in which tumors at a single histogenic site (hepatocytes) were increased in incidence in rats and mice. Earlier, less sensitive studies found no carcinogenic effects, and there is no evidence from epidemiological studies that DEHP is carcinogenic. Several schemes have been developed for assessing the strength of evidence that a particular chemical is a human carcinogen. (20) (21) (22) In all 3 of these classification schemes, DEHP is assigned to a low category because the evidence of its carcinogenicity is relatively weak, since it comes only from experimental animals, based on neoplasms occurring at a single histogenic site, induced at a relatively high dose level, with no supporting evidence of genotoxicity (see following section). This fact should be taken into account when the significance of the risk is considered.
GENOTOXICITY
The overwhelming preponderance of evidence indicates that DEHP and its metabolites, MEHP and 2-ethylhexanol, are not genotoxic (Table 3) , though a few studies have reported positive results, mostly with MEHP. These are discussed briefly below.
DEHP has been found nonmutagenic in at least 8 separate Ames assays. Only Tomita et have reported positive results, and their data are not convincing: results of only a single dose were reported, and the increase was less than 2-fold. Tomita et a1.I3O) also reported increased chromosomal aberrations and transformation in embryonic cells from Syrian hamsters treated transplacentally with DEHP at 3.75-15 g/kg administered by gavage. It might be noted that the proportion of normal diploid cells in all cultures including the controls was low (40-70%), suggesting chromosomal instability or technical deficiencies in experimental procedures.
The significance of the apparent positive results in the transformation assay is unclear, since the increase is small, and it would be desirable to repeat the study to show that the results were not due simply to variations in background transformation frequency in different animals. This test system is not directly comparable to the 3T3-system used by Barber et al.,(z9) since the latter is entirely in vitro and the former involves treatment in vivo, permitting full metabolic activity. The possibility of a difference between in vivo and in vitro systems is also raised by the weakly positive results in dominant lethal assays in mice reported by Singh et a1.144) and Autian.145) Interpretation of effects in the study by Singh et al.(44) is difficult because mice treated at the high dose (25.56 ml/kg) had reduced fertility, which might be expected, since high doses of DEHP cause testicular degeneration in ratsIso s l ) and mice.'') Hence, increases in early fetal deaths may be an indication of testicular toxicity rather than mutagenicity. Effects at lower doses (1-10 ml/kg) reported by A~t i a n '~~) are not statistically significant.
Albro et al. 14') reported "association" of radioactivity with DNA when I4C-DEHP with label in the ethylhexyl moiety was fed to rats. No association occurred when the label was in the phthalate group or when DEHP was saponified to phthalic acid and free 14C-ethylhexanol before being fed. The lack of an effect with 14C-ethylhexanol suggests that labeling is not due only to incorporation of label into a general metabolic pool. However, Von Daniken et al.,14s) while finding similar association of radiolabel from DEHP with DNA under similar circumstances, also found label in DNA when I4C-ethylhexanol was given orally. They presented evidence that the results with DEHP were ciaused by metabolism and incorporation of label into nucleotides and not due to covalent DNA binding of the type seen with genotoxic carcinogens. More recent work by Albro et a1.(52) also indicates that association of label from 14C-DEHP is due to catabolism of the ethylhexyl moiety and incorporation de novo into normal DNA nucleotides.
h4EHP
Once again most of the reported positive results come from Tomita et al.
They report a doserelated increase in toxicity to rec-compared to rec+ Bacillus subtilis. This seems to be a genuine effect, since consistent results were obtained over a range of doses (100-500 mg/disc). These authors also report an apparent dose-related increase in revertants in Salmonella (TA 100) and Escherichia coli (WP2 B/r) treated with MEHP in suspension. The results are reported in terms of revertants/ survivor. This method of reporting results can be misleading unless the protocol used is appropriate. For example, the standard Ames assay with Salmonella involves plating the bacteria in the presence of a small amount of histidine. If histidine is incorporated following suspension treatment, a treatment that is simply toxic can appear to be mutagenic, since the number of spontaneous revertants appearing is governed by the number of cells that the histidine can sustain not by the number of RISK ASSESSMENT OF DEHP No increase in chromosomal aberrations in peripheral lymphocytes of workers exposed to DEHP for average of 22 years DEHP at 5, 1.7, and 0.5 g/kg per day for 5 days by gavage caused no increase in chromosome aberrations in bone marrow cells in male rats DEHP negative in micronucleus test in mice at 5 g/kgsingle dose and 5 g/kg per day for 5 days Apparent increase in chromosomal aberrations in cells cultured from hamster embryos treated with DEHP transplacentally at 7.5 and 15 g/kg DEHP at 25.56 mg/ml (2/3 IP LD50) in male mice caused reduced fertility, reduced litter size, and increased early fetal deaths in first 3 weeks after treatment; slight effects at 1/2 and 1/3 LD,, Slight but not significant increases in early fetal deaths at 1-10 ml/kg DEHP at MTD (9.86 g/kg) and 1/2 and 1/4 MTD by gavage daily for 5 days was negative in dominant lethal assay in mice No increase in transformation in mouse 3T3 cells in vitro at 0.875-21.0 nl/ml without metabolic activation or at 6.25-100 pl/ml with rat hepatocytes to provide activation Apparent increase in frequency of transformation in cells of hamster embryos treated transplacentally at 7.5 and 15 g/kg Some incorporation of radiolabel into liver DNA in rats fed 14C-DEHP with label in ethylhexyl moiety but not if labeled in phthalate moiety; nature of attachment to DNA unclear Similar results to those of Albro et al., (47) In vitro cytogenetics MEHP negative at 0.013-0.32 pl/ml in mouse lymphoma TK assay f S9 MEHP negative at 0.081-1.25 mM in CHO/HGPRT mutagenicity assay Apparent dose-related increase in differential inhibition in repair-deficient bacteria (Rec assay) MEHP at ''toxic and nontoxic levels" negative in primary rat hepatocyte UDS assay MEHP induced significant increases in chromosome aberrations in CHO cells at 0.8-1.75 mM but no increase in SCEs at 0.7-1.3 mM Apparent increase in SCEs in V79 cells at 25-50 pg/ml MEHP at 0.14, 0.05, and 0.01 g/kg per day for 5 days caused no significant increase in chromosome aberrations in bone marrow cells Apparent reproducible increase in the frequency of micronucleated cells in bone marrow of female mice given IP doses of MEHP at 125 mg/kg per day on 2 successive days; no effect with a single dose or in males Apparent increase in chromosome abnormalities in cells from hamster embryos treated transplacentally at 375-1500 mg/kg MEHP at 50, 100, and 200 mg/kg per day for 5 days by gavage was negative in assay in mice MEHP negative in mouse 3T3 transformation test at 25-120 nl/ml without metabolic activation and at 5-125 nl/ml with rat hepatocytes to provide activation
2-Ethylhexanol
Negative in Ames assay f S9 at 0.01-1.0 pl/plate Negative in 5 strains in Ames assay f S9 at 0.002-1.8 pl/plate Small (less than 3-fold) increase in mutation frequency matched by reduction in survival with 2-EH at 0.5-1.5 mM Negative in Ames strains TA98 and TAlOO f S9 at 0.1-10 mM Urine from rats given 2-EH by gavage at 2 g/kg per day for 15 days was negative in Ames assay f S9 and f 6-glucuronidase/ar ylsul f atase Negative in mouse lymphoma assay at 0.018-0.24 pl/ml f s9 2-EH negative "at nontoxic and toxic levels" in primary rat hepatocyte UDS assay Negative in CHO chromosome aberration assay at 1.5-2.8 mM comments on these findings are the same as those we made in connection with the work of these investigators on DEHP. They also report a small increase in SCEs in Chinese hamster V79 cells treated in vitro with MEHP at 25-50 mg/ml for 24 hours and mention-but give no details of-an increase in mutations in the azaguanine/thioguanine resistance system with V79 cells in vitro and Syrian hamster embryo cells treated transplacentally.
Overall, the report of Tomita et a1.I3O) suffers from a lack of details about the procedures used. Without this and some of the supporting data that are missing from the report, a detailed evaluation is impossible. However, some of the reported positive results are in systems sufficiently different in endpoint (B. subtilis rec assay) or method of treatment (transplacental assays) from other published negative results that they can not simply be considered inconsistent (e.g., if intact mammalian metabolism is needed for expression of activity, Tomita's positive results with transformation do not necessarily conflict with the negative results found by Barber et a1.(2y) in 3T3 cells in vitro).
Yagi et a1.(z4) report in an abstract that MEHP "showed DNA-damage provoking activity in B. subtilis and mutagenicity in E. coli," but no details are given. Some of these authors are from the sa.me laboratory as Tomita et al., (30) and they may be reporting data from the same studies.
Phillips et al. (40) reported an increased frequency of chromosomal aberrations in Chinese hamster (CHO) cells in vitro treated for 2 hours with MEHP at 0.8-1.75 mM. In particular, there was a doserelated increase in chromatid interchanges in addition to increases in chromatid and chromosome breaks. These does levels were in the toxic range and reduced cell survival to between about 65% to less than 10% of control values. Unlike Tomita et a1., No effects were seen in males given this treatment or in either sex given a single dose of 125 mg/kg. Although the increase was significant when compared to a concurrent solvent control group, the frequency observed was within the range of historical control values.
Albro et a1.(471 found "association" of label with DNA when I4C-MEHP labeled in the ethylhex-an01 moiety was fed to rats. Labeling was less than resulted with an equivalent amount of I4C-DEHP. The nature of this "association" is not known for certain, but the study by Von Daniken et mentioned above in relatior. to DEHP suggests that incorporation of label via intermediary mLetabolism may be responsible.
RISK ASSESSMENT OF DEHP
The only suggestion of positive results with 2-ethylhexanol comes from an azaguanine-resistance assay in Salmonella. (49) There was a slight, apparently dose-related increase in azaguanine-resistant mutants in bacteria treated with 0.5, 1 .O, and 1.5 mM EH. The increase in frequency of mutants/ survivor was small (less than 3-fold) and was matched by a reduction in survival, however, so that there was no increase in the absolute number of mutants at any dose. Such a response is not generally considered conclusive evidence of mutagenicity.
Discussion
As we have noted and as is evident from Table 3 , the overwhelming preponderance of evidence suggests that DEHP, MEHP, and 2-EH have little or no propensity for direct interaction with and alteration of DNA. A few studies suggest genotoxic activity, but, as described above, in most of these cases serious questions exist regarding methodology or the significance of the results. However, there are a few findings that cannot be dismissed, and it appears that there remains some uncertainty regarding the capacity of at least MEHP to display some degree of genotoxic potential in some systems.
If the proposed mechanism of DEHP carcinogenesis is correct (see next section), one would expect genetic damage to be induced in vivo (or in in vitro systems with peroxisomes present) at doses capable of inducing peroxisome proliferation. In this sense DEHP/MEHP may be threshold genotoxic agents, which would not be expected to display genotoxic activity if the test systems used did not provide for the presence of peroxisomes or if the DEHP/MEHP doses were insufficiently high to cause peroxisome proliferation.
MECHANISM OF TUMOR INDUCTION IN RODENTS
Recent investigations into possible mechanisms of chemical carcinogenesis have emphasized that more than one biological process may be involved in cancer development.(53) The influential work of the miller^(^^,^^) emphasized the fact that a large proportion of known carcinogens either are themselves, or are metabolized to, electrophiles. These react with and damage nucleophilic sites in the cell, particularly DNA, and are, therefore, genotoxic. Damage to DNA provides a basis for explaining the permanent nature of the neoplastic state on the basis of a heritable (at the cellular level) alteration in the genome.
Although the ability to damage DNA seems to be an important property of many carcinogensthe so-called genotoxic carcinogenssome substances appear to increase the incidence of tumors in experimental animals without interacting directly with DNA. Examples include tumor promoters and cocarcinogens, such as phorbol esters, that increase the incidence of tumors when applied in conjunction with a genotoxic carcinogen, and some hormones, particularly estrogens.(s3) Also included in this group of epigenetic or nongenotoxic carcinogens are such chemicals as saccharin, DDT, and perhaps carbon tetrachloride.(53) As discussed in the previous section, DEHP has no substantive genotoxic activity and, therefore, belongs in the general class of nongenotoxic carcinogens. Several hypotheses have been proposed to explain the mechanism of action of various nongenotoxic carcinogens. (53) Thus, immunosuppressive drugs may permit tumors to develop from transformed cells that would normally be detected and destroyed by the body's immunological system. Some chemicals may alter the activation or detoxification of other carcinogens so that higher levels of an active metabolite are present.
There is considerable support for the hypothesis that DEHP belongs to a diverse class of nongenotoxic carcinogens whose mechanisms of action involve induction of peroxisome proliferation. (28, 56) In this section, the support for this hypothesis and its implications concerning the shape of the dose-response curve for tumors in rodents and, hence, its implications for assessing the risk of tumor development at low doses are discussed.
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TURNBULL AND RODRICKS There is one other aspect of the behavior of DEHP that influences the dose-response relation, and this is the relationship between administered dose and target-site dose over a range of dose levels (i.e., dose-related pharmacokinetics). The term "target-site dose" is used here to mean the dose in the target organ (liver) of the substance (DEHP or one or more of its metabolites or by-products of its metabolism) that is ultimately responsible for causing (directly or indirectly) the observed increase in the incidence of liver tumors. The term has been used in the past to refer to the dose of a genotoxic, active metabolite of a proximate carcinogen. We use the term here in a more general sense, with no irnplication of genotoxicity. A study of the dose-related pharmacokinetics of DEHP in rats has recently been completed, and the results of the study appear to be useful for defining the likely dosert:sponse relation. (s7) We first describe the data concerning the peroxisome proliferation hypothesis and then discuss the data on dose-related pharmacokinetics. The implications of these sets of data for the dose-response relationship are discussed subsequently.
PEROXISOME PROLIFERATION HYPOTHESIS
The nature and function of peroxisomes have been the subject of several recent reviews.(58-60) Elriefly, peroxisomes are small (0.2-1.5 mm) cytoplasmic organelles bounded by a single limiting membrane enclosing a granular matrix. They are found most frequently in the liver and kidney but also in other tissues. They appear to be more common in rodents than in humans or other primates, but peroxisomes or similar organelles are found throughout the animal and plant kingdoms.
The most characteristic enzyme of peroxisomes is catalase, which catalyzes the breakdown of hydlrogen peroxide to water: ( 6 0 ) or HZO2 t RH2 -2 HZO t R This is an important function, since hydrogen peroxide itself or the hydroxyl ion (OH') that is formed from hydrogen peroxide by the Haber-Weiss reaction(61) is known to damage DNA and chromosomes.
In addition to catalase, which breaks down hydrogen peroxide, peroxisomes contain several enz.ymes that catalyze reactions that generate hydrogen peroxide. These include several oxidase enzymes, such as t-a-hydroxyacid oxidase, D-amino acid oxidase, and urate oxidase.
Recent studies have demonstrated that peroxisomes contain a system of enzymes involved in the @-oxidation of fatty acids, which also generates hydrogen peroxide. ( 7 1 ) The hypothesis that there is a relationship between peroxisome proliferation and liver carcinogenesis in rodents was proposed by Reddy et on the basis of their findings with a structurally diverse group of chemicals, including some drugs used in the treatment of hyperlipidemia (clofibrate, nafenopin, Wy-14,643, BR-931, and tibric acid). All 5 of these chemicals caused hypolipidemia (reduction in serum lipid levels, particularly triglyceride levels), liver enlargement (hepatomegaly) without necrosis, proliferation of liver peroxisomes, and hepatocellular carcinoma in mice or rats, but none were mutagenic in the Ames assay or caused DNA damage in the lymphocyte 3H-thymidine incorporation assay. Since then, additional chemicals have been found to display this same set of effects. ( 7 2 ) Although an association between peroxisome proliferation and development of hepatic tumors seems clear for several chemicals, there may be some exceptions. Acetylsalicylic acid (aspirin) is a weak inducer of peroxisome proliferation, but there is no evidence that it is carcinogenic. ( 7 2 1 Fenofibrate, a hypolipidemic drug related to clofibrate, caused hypolipidema, heptatomegaly and peroxisome proliferation in Sprague-Dawley rats at dose levels of 50-1000 mg/kg per day for 3 months, but no significant increase in liver tumors was seen in Sprague-Dawley rats fed fenofibrate at 10 or 60 mg/kg per day for 117 weeks or in Swiss mice fed fenofibrate at 50 mg/kg per day for 92 weeks.(73) However, the dose levels used in the carcinogenicity studies were fairly low and probably RISK ASSESSMENT OF DEHP did not represent maximum tolerated doses as used by NTP with DEHP. It is, therefore, unclear whether fenofibrate is a true exception to the correlation pattern or whether testing at higher dose levels would reveal carcinogenic effects. This is highlighted by studies with bezafibrate, another hypolipidemic drug related to clofibrate. Although bezafibrate caused hypolipidemia, hepatomegaly, and peroxisome proliferation in rats at dose levels of 10-500 mg/kg per day for 1 week, it caused no increase in liver tumors in Sprague-Dawley rats when fed at 300, 750, or 1500 ppm for 24-26 months.(74) However, when the dose level was increased to 6OOO ppm in the diet, liver tumors developed in the female rats. ( 7 5 ) In considering how chemicals that cause peroxisome proliferation might induce cancer, one may start by examining data on the physiological and biochemical effects of peroxisome proliferation that might be relevant to carcinogenicity. Reddy and ~o -w o r k e r s (~~.~~) have proposed that increased production of hydrogen peroxide by the peroxisomes is responsible for the carcinogenic effects. Evidence for this mechanism is incomplete, but it appears to be the best available explanation for the carcinogenic activity of DEHP in rodents.
Although peroxisomes contain several enzymes that catalyze reactions in which hydrogen peroxide is produced, (58.60.76) most of these enzymes are little affected by chemicals that cause peroxisome proliferation. ( 7 L ) However, peroxisomal enzymes involved in @-oxidation of fatty acids (which form hydrogen peroxide as a by-product) are substantially increased in activity in liver cells from rats fed hypolipidemic drugs that cause peroxisome proliferation. (7L.77) Similarly, induction of peroxisomal @-oxidation has since been demonstrated with DEHP . (78-8*) The pathway for peroxisomal @-oxidation of fatty acids is illustrated in Figure 3 . As indicated there, the reduced FAD produced by fatty acyl-CoA oxidase is coupled directly to oxygen, producing hydrogen peroxide, rather than being coupled to the respiratory chain, as it is in the mitochondria.(60,71) Because it is not coupled to the respiratory chain, the peroxisomal @-oxidation pathway is insensitive to cyanide; thus, an independent measure of peroxisomal @-oxidation can be made by using cyanide to inhibit selectively mitochondrial @-oxidation. Figure 5 ) also induce @-oxidation and may be the proximate inducers of peroxisome proliferation.
Of particular importance to our consideration of mechanism of carcinogenesis, these increases in @-oxidation activity were not accompanied by correspondingly large increases in catalase activity. (78.80-82) This difference in extents of increase in @-oxidation and catalase activity is important because, as mentioned before, catalase normally inactivates the potentially hazardous hydrogen peroxide generated by the @-oxidation system, although glutathione peroxidase also plays a role in disposing of hydrogen peroxide. Since the increase in @-oxidation activity induced by DEHP is much greater than the increase in catalase, it is possible that this creates an imbalance, resulting in excess levels of hydrogen peroxide in the cell. In addition to these effects of hydrogen peroxide itself, it can form the highly reactive hydroxyl radical either by spontaneously splitting to form 2 hydroxyl radicals (62) or by reacting with ferrous iron: (87) Fe I1 + H20, -Fe 111 + OH-+ OH' or by reacting in the Haber-Weiss reaction with superoxide ion, which may be generated by the microsomes: 
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The hydroxyl radical is highly reactive and can cause DNA damage directly,(6L.62) or it can initiate lipid peroxidation, which in turn yields several chemicals, such as fatty acid hydroperoxides, cholesterol hydroperoxide, endoperoxides, fatty acid and cholesterol epoxides, enals and other aldehydes, and alkoxy and hydroperoxy radicals that have been shown to exert mutagenic, promoting, or carcinogenic effects. (91) It is recognized that there are limitations to this hypothesis. The most important of these limitations is that there is no evidence that excess levels of hydrogen peroxide are generated in the livers of rats fed high levels of DEHP. Nor is there evidence of toxic effects, such as lipid peroxidation, that might be expected to accompany excess levels of intracellular hydrogen peroxide. However, it is not clear to what extent such effects have been looked for, and there is some evidence of increased steady-state levels of hydrogen peroxide and increased levels of lipofuscin (indicative of lipid peroxidation) in the livers of rats treated with other peroxisome proliferators. I")
The proposed mechanism of carcinogenicity is summarized in Figure 4 , which shows only the essential outline of the peroxisome proliferation hypothesis. It is not intended as a comprehensive description of the fate and biological effects of DEHP.
DOSE-DEPENDENT PHARMACOKINETICS OF DEHP
Before discussing the available data on the pharmacokinetics of DEHP in rodents, it would be useful to review briefly the major pathways of metabolism of DEHP. Our understanding of the metabolism of DEHP is due largely to the work of Albro and co-workers, on whose work the following summary is based. The influence of dose level and previous exposure on the metabolism of DEHP in rats has been investigated.(57) The most important finding in the context of this risk assessment was that in rats with prior exposure to DEHP, the percentage of the dose excreted in urine as metabolite I increased dispr'oportionately with increased dose. The percentage of the dose excreted in the urine as metabolite I doubled from about 11% of the dose at lo00 ppm to about 25% of the dose at 6OOO ppm, and more tban doubled to 31 070 of the dose at 12,000 ppm. This increase in the percentage of the dose excreted in urine was offset by a decrease in the percentage of the dose excreted in feces, partially by a decrease in the percentage excreted as metabolite IX.
Metabolite I is believed to be formed by /?-oxidation of metabolite V,(921 and the urinary excretion patterns observed for these metabolites were consistent with this pathway. Therefore, repeated admiinistration of DEHP at 6OOO and 12,000 ppm in the diet to rats apparently results in a nonlinear increase in metabolism by /?-oxidation.
It thus appears that there is a nonlinear relationship between administered dose and the active dose of DEHP metabolites. By "active," we refer to that which produces peroxisome proliferation, an1 indirect measure of which is probably production of metabolite I by /?-oxidation of metabolite V. metabolite I has not been identified in humans and is only a minor metabolite in p~irnates,(~~.'~) a P-RISK ASSESSMENT OF DEHP It is possible, however, that some of the enhanced conversion of metabolite V to metabolite I is attributable to mitochrondrial oxidation as well as to peroxisome proliferation.
The 6OOO ppm and 12,000 ppm exposure levels used in this study were identical to those used in the NTP bioassay, which lead to the appearance of an excess of liver tumors. This study reveals that a marked shift in the production of metabolite I (and in the pattern of other metabolites as well) occurs between the lo00 ppm level and the higher levels. This observation strongly suggests that the dose-response relation for peroxisome induction (and subsequent tumor induction) may decline in a nonlinear fashion below the region of observed tumorigenic responses.
DOSE-RESPONSE EXTRAPOLATION OF RODENT DATA
In order to estimate the risk to humans of exposure to DEHP in the environment, it is necessary to estimate the relationship between risk and exposure levels in the low range to which humans may be exposed. As a first step, we need to extrapolate the observed relationship between DEHP dose and tumor incidence in rodents to low dose levels. Several mathematical models have been developed and proposed for extrapolating from observed data on tumor incidence at high experimental doses to risk at low doses.(85,95.96) Which of these models is most appropriate to use in any particular case is an important and controversial aspect of risk assessment methodology. Some of the controversy arises because in some cases the various models predict risks at low exposure levels that differ by several orders of magnitude, even though they may all fit the experimental data in the high exposure range almost equally weil. For example, in the preamble to OSHAs Cancer Policy (45FR 5200), estimates of lifetime risks to humans from vinyl chloride and saccharin at likely exposure levels are presented. These estimates vary 1 million-fold depending on which extrapolation model is used.
In selecting a model for carcinogenic risk assessment, the functioning of the model should be consistent with the scientific information on the phenomenon being modeled. In the present case, it is desirable that at least some of the models used should be consistent with our limited understanding of the possible mechanism(s) of carcinogenicity of DEHP.
In conducting dose-response extrapolation, the dose in question is generally the applied dose of the chemical, usually expressed in terms of mg/kg body weight per day. However, probably of more importance in determining how the risk will change with dose is the dose of the ultimate carcinogen at the target site. This latter dose will be a function of the phannacokinetics of the chemical (its absorption, distribution, biotransformation, and elimination). As long as all of the phannacokinetic parameters of a chemical are linear with dose, any increase in applied dose will cause a proportional increase in what we may call the "target-site dose," but at high doses processes such as absorption, biotransformation, and excretion may become saturated, and there will no longer be a linear relationship between applied dose and target-site dose.'97.98) As an example of the application of this phenomenon, Gehring et al. w9) examined data on the carcinogenicity and pharmacokinetics of vinyl chloride. They demonstrated that metabolism of vinyl chloride was not linearly related to applied dose but followed Michaelis-Menten kinetics.
The situation with DEHP is different from that with vinyl chloride, which is a genotoxic carcinogen whose biotransformation to an active carcinogenic form is apparently saturated at high dose levels. In the case of DEHP, our proposed mechanism involves peroxisome proliferation and, perhaps, subsequent excess production of peroxide and other active oxygen species at high dose levels. If this model is correct, the target-site dose in which we are interested is that of the various active oxygen species. Unfortunately, no data are currently available to measure this target-site dose directly. Instead, an indirect measure is proposed, recognizing the many uncertainties in the use of such a measure.
This indirect measure is the level of urinary excretion of DEHP metabolite I. This is assumed to provide a surrogate for the true target-site dose, which is a function of the effects of DEHP on the peroxisomes, perhaps involving a metabolic disturbance or the generation of active oxygen species. There is circumstantial evidence that production of metabolite I may serve as an indicator of peroxisomal activity and perhaps of active oxygen generation. First, metabolite I is probably produced as a 127 TURNBULL AND RODRICKS result of fl-o~idation;'~~) second, production of metabolite I is increased at high dose levels of DEHP;(57) and third, peroxisomal @-oxidation activity increases substantially at similar dose levels. (78) (79) (80) (81) (82) There is uncertainty in using metabolite I as a surrogate for target-site dose. We do not know whether metabolite I is formed in the peroxisomes or in the mitochondria (or other cellular compartment). Obviously, production of metabolite I in the mitochondria would not be an indicator of peroxisomal activity and would not involve peroxide generation. Thus, the use of metabolite I piroduction would overestimate peroxisomal activity and peroxide generation to the extent that mitochondrial P-oxidation is involved in metabolite I production. However, the involvement of the peroxisomes in the production of metabolite I is supported by the results of recent studies by Lhuguenot et a1.,(100-102) who examined the effects of dose and time of the metabolism of MEHP using Wistar rats in vivo and rat hepatocytes in vitro. They found that both in vivo and in vitro production of metaibolite I increased in parallel with increases in cyanide-insensitive peroxisomal 0-oxidation activity. Also the change in rate of production of metabolite I from metabolite V with time of the hepatocytes in culture mirrored the change in the activity of cyanide-insensitive palmitoyl CoA oxidation in the hepatocytes.
That mitochondrial P-oxidation may also be involved in metabolite I production is suggested by reports of increases in the activity of enzymes involved in P-oxidation in both peroxisomes and mitochondria after treatment of rats with DEHP. ( 7 9 . 8 0 ) However, provided the mitochondrial contribution to metabolite I production does not increase with dose of DEHP to a greater extent than the peroxisomal contribution, the use of level of metabolite I production as a surrogate for peroxisomal activity and, peroxide level will at least not underestimate the true values.
In the past, pharmacokinetic data have been used to estimate target-site doses of genotoxic carcinogens, and these dose estimates have been used in place of measures of applied dose in risk extrapo-latiomt9' In assessing the risks of DEHP, we may use our knowledge of the nonlinear relationship between applied dose of DEHP and urinary excretion of metabolite I to provide a surrogate to estimate the presumed nonlinear relationship between applied dose of DEHP and peroxisome activity, which is in turn an indicator of the target-site dose of peroxide or other active oxygen species. To do this, it is necessary to examine the quantitative relationship between daily dose of DEHP and excretion of metabolite I under conditions approximating those of the NTP bioassay. Data for this are derived from the Little study of metabolism of DEHP in male rats fed DEHP at 1000, 6000, and 12, OOO ppm in the diet for 20 days before receiving I4C-labeled DEHP at the same dietary levels.(57) These data are presented in Table 4 . 
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RISK ASSESSMENT OF DEHP best fitting the data ( r = 0.9996). This equation is used to adjust the doses in the NTP bioassay to give doses that are surrogates for the target-site dose before fitting extrapolation models to the bioassay dose-response data. Because of the uncertainties outlined above, this adjustment must be considered only semiquantitative. However, the uncertainties are such that the adjustment is likely to overestimate risk at low dose levels and, hence, be conservative.
Choice of extrapolation methods
A review of the various extrapolation models that have been used for risk assessment reveal that no single model is clearly the most appropriate for use with DEHP. We have, therefore, used several procedures for low dose extrapolation: arises in a single cell and is expressed after the cell or its progeny have passed through k transitions, the rates of one or more of which are proportional to the concentration of the carcinogen at the target site.(108) Some carcinogens may act at the first stage of the process (so-called initiators or earlystage carcinogens), others may act only at later stages (promoters or late stage carcinogens), and still others may act at both early and late stages of the process of tumor development (so-called complete carcinogens). In the general case, where mechanisms are unknown, it has become the practice to adopt the linearized multistage model. The Mantel-Bryan probit model is another commonly used model. (109,110) It was designed to calculate a lower confidence limit for a "virtually safe" dose of a carcinogen by extrapolating dose-response data using an arbitrary slope of 1 probit per log dose unit. The slope was chosen by Mantel and Bryan as being shallower than those observed in empirical data.(109) Because of the arbitrary slope, this procedure does not (and is not intended to) give a valid estimate of risk at a specific low dose level (as opposed to an estimate of "safe" levels). The model is also not supported by our understanding of the biology of cancer. However, it is useful for showing the range of uncertainty regarding the possible risk at low dose levels.
The multistage model assumes additivity of background, which leads to low dose linearity, ( I o 4 )
whereas the Mantel-Bryan probit model assumes that the mechanism of the carcinogen is different from that of whatever causes the background incidence of tumors. Hence, risk may not be linear at low dose levels. Because DEHP seems to act by a mechanism involving peroxisome proliferation, which is not likely to contribute to the background tumor incidence, the Mantel-Bryan procedure may be more appropriate to the case of DEHP. With both models, surrogates for target-site doses are used in addition to applied doses of DHP because, as explained above, there is reason to believe that the mechanism by which DEHP induces liver tumors in rodents depends on the production of excess peroxide and active oxygen species, and indicator of which may be the level of production of metabolite 1. The production of metabolite I in rats and, hence, presumably, of peroxide, is not Enearly related to the dose level of DEHP.
The threshold model (application of a safety or uncertainty factor to a NOEL) is of the type normally used to predict safe levels of exposure (acceptable daily intakes, ADIs) for noncarcinogenic effects.'"') We use it here, since if our hypothesis regarding the mechanism of DEHP-induced carcinogenesis is correct, liver tumors are likely to occur only at doses that induce peroxisomal (3-oxidation systems. Since there is likely to be a threshold for peroxisome proliferation and enzyme induction, there is also likely to be a threshold for carcinogenicity.
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TURNBULL AND RODRICKS Although we have not used them for this study, other extrapolation models, such as the Weibull or multihit models, may also be appropriate for low dose extrapolation. 1L06.107)
Modeling of rodent carcinogenicity data
In estimating low dose risks to rodents, data derived from the NTP bioassay were used. TO provide a conservative estimate of risk, the combined incidences of hepatocellular carcinoma and adenioma/neoplastic nodules were used. Also, to provide a better estimate of the background tumor incidence, pooled controls were used, combining data from the bioassays that were performed in the same room of the same laboratory at the time as the DEHP bioassay. Thus, control data from bioassays of DEHP, butylbenzylphthalate, guar gum, and di(2-ethylhexyl) adipate were used. The dose levels in mg/kg per day estimated by NTPIZ) on the basis of food consumption were used. The 4 data sets used for risk extrapolation are presented in Table 5 . Included in Table 5 are the estimates of the surrogate target-site doses based on the expected urinary levels of metabolite I for rats. These are derived as described above using data from the multidose metabolism study. Is') Since this metabolism study involved only male rats, the adjustment, strictly, is applicable to male rats. However, we have ailso conservatively applied the adjustment to the female rat data, since these data predict slightly higher risks. Corresponding data are not available for mice. Therefore, no such adjustments are rnade for the doses administered to mice; although a similar nonlinear relationship between applied close of DEHP and "target-site dose" probably also occurs in mice.
The computer program Global 82 written by Howe and Crump of Science Research Systems, Inc., Kuston, Louisiana, was used to perform low dose extrapolation using the multistage model, A computer program was also used to perform low dose extrapolation by the Mantel-Bryan probit procedure. As discussed earlier in the description of low dose extrapolation models, the Mantel-Bryan probit procedure was not intended by its authors to provide valid estimates of low dose risk. Hence, the program used generates estimates of "virtually safe dose" (VSD). The VSDs we report here correspond to lifetime risks of less than (1 in 1 million) and The results of applying the multistage model to all four data sets in Table 5 are presented in Table  6 , which presents the dose coefficients q, and q2 from the multistage model that best fit the data using the daily doses of DEHP. Also included are the values of ql*, the upper 95th percentile confi-(1 in 100 million). : P(d P ( d ) is the probability of developing a tumor after lifetime exposure to a dose of d mg/kg per day. For small values of d, the excess risk of developing a tumor closely approximates (qld + qpl'). Also tabulated is ql*, the upper 95th percentile confidence limit on ql. dence limit on q l . At low dose levels, the excess risk above background to rodents is closely approximated by:
where P(d) is the risk at dose level d and q1 and q2 are the estimated dose coefficients. The upper confidence limit on low dose risk is closely approximated by: Table 7 lists the corresponding values of q l , qz, and ql* derived using the surrogate target-site dose values. To derive the risk estimate for a given dose (d) of DEHP using these values, it is first necessary to convert the DEHP dose to the corresponding surrogate dose (Z) using the equation:
The risk is then derived using the dose coefficients as described above. P ( d ) is the probability of developing a tumor after lifetime exposure to a dose of d mg/kg per day. For small values of d, the excess risk of developing a tumor closely approximates (qld + qp12). Also tabulated is ql*, the upper 95th percentile confidence limit on q,. bAlthough the data on metabolite I levels were derived from studies in male rats only, they are applied to females for purposes of conservative risk assessment, since the female data predict slightly higher risks, recognizing the uncertainty of applying metabolic data derived from one sex to the other. Table 8 lists the values of "virtually safe dose" corresponding to a risk of and lo-' predicted by the Mantel-Bryan probit procedure when applied to the data on each species for the sex that showed the higher risk (female rats and male mice). 
INTERSPECIES EXTRAPOLATION: RODENTS TO HUMANS
The risks per unit of exposure (or NOELS) derived by application of the various models listed in the previous section pertain strictly to mice and rats. The next stage of analysis involves extrapolation of these risks to humans. Extrapolation between species adds considerably to the uncertainty of risk assessment, as has been discussed by many individuals from such groups as the National Academy of Sciences, ( 3~1 1 1 ) the Interagency Regulatory Liaison Group, ( 8 5 ) and the Scientific Committee of the Food Safety Council. (95) In the preamble to its Cancer Policy (45 FR 5200), OSHA discussed many of the complications of interspecies risk extrapolation and concluded:
Extrapolation from animal data to predict risks in humans introduces many additional uncertainties. These include selection of appropriate scaling factors for size, lifespan, and metabolic rate; differences in routes of exposure, duration and schedule of exposure, absorption, metabolism, and pharmacokinetics; differences in intrinsic susceptibility and repair capabilities; intra-population variation and susceptibility; and exposure to other carcinogens and intrinsic and extrinsic modifying factors. At least theoretically, these factors can affect the relative response of humans and animals by many orders of magnitude.
There follows a discussion of some of these factors, as they apply to interspecies extrapolation for DE.HP, and the major approaches that have been proposed to take them into consideration.
Unit of dosage measurement
Consideration of an appropriate dosage unit encompasses consideration of animal size, lifespan, and, to some extent, metabolic rate. In specifying a unit of dose there are generally three factors involved: a measure of the amount of the substance administered (mg, ml, mmole, and so on), an indication of the size of the organism (kg body weight, m2 body surface area, blood volume, and so on), and some indicator of time (day, lifetime, and so on). Among the most commonly used units of dose are mg/kg body weight per day, mg/kg body weight per lifetime, and mg/m2 body surface 132 RISK ASSESSMENT OF DEHP area per day. Debates over the choice of dosage unit have centered on the appropriate measure for body size (kg body weight or m2 body surface area) and on the temporal descriptor (per day or per Hoe1 et a1. (112) proposed the use of dosage units in mg/m2 body surface area per day on the basis of studies of the acute toxicity of anticancer drugs in humans and animals. (115) In these studies the acutely toxic level was similar in mouse, rat, hamster, dog, monkey, and man when dosage was expressed as mg/m2 per day. This procedure has also been adopted by the Environmental Protection Agency (106) and is the procedure used by the Consumer Products Safety in its risk assessment of DEHP. However, the relationship between dose and body surface area, determined on the basis of acute drug toxicity, a priori means very little when considering chronic effects, such as cancer. Given the uncertainty about the factors contributing to carcinogenicity, the most appropriate basis for judging the suitability of a species-to-species conversion factor is empirical data on the relative susceptibilities of different species.
What few relevant data exist have been analyzed by Crump et al.,('05) who concluded that the dosage measurement giving the closest correlation between species was mg/kg body weight per day. In the absence of good evidence for the use of a more complex procedure, we propose the use of mg/kg per day as a generally acceptable basis for interspecies dosage comparison. In addition to its relative simplicity, this procedure appears to have the best empirical support. (Io5)
All of the foregoing discussion and almost all of the discussion in the scientific literature concern the relative merits of the possible measures of body size and temporal factors. Little attention has been paid to the appropriateness of the measurement of the amount of substance applied (usually measured in milligrams). In cases where the administered dose is linearly related to the dose of the active carcinogen at the target site, a direct measure of the amount applied is appropriate. However, as alluded to earlier, in cases where nonlinear pharmacokinetics apply, measurement of the dosage in terms of the material applied may be inappropriate, and, where available, pharmacokinetic data should be used to modify the dosage measurement so that the units of dosage are an indication of the level of the ultimate carcinogen at the target site. Alternatively, one might actually measure the amount of an active metabolite of a precarcinogen or measure DNA interactions to estimate the target site dose. This would not be necessary if the pharmacokinetic parameters were the same in both the experimental species and in humans. However, in many cases, the rates of production and inactivation of active metabolites are likely to have species differences. For example, the rate of production of active metabolites of chloroform, perchloroethylene, and 2-acetylaminofluorene (AAF) differs in different species and is correlated with the relative carcinogenic potency of the particular chemical in the different species. (98.116.117) lifetime). (95.105.112-114) 
Route, duration, and schedule of exposure
In the NTP Bioassay of DEHP, animals were fed DEHP at a uniform concentration in the diet continuously from the age of about 5-6 weeks (i.e., after about 1/20 of their lifespan had elapsed) for the subsequent 103 weeks. In contrast, although some dietary exposure may occur, human exposure to DEHP is likely also to involve inhalation of low levels of DEHP vapor released from PVC products, dermal contact with products containing DEHP, some of which may be absorbed through the skin, and, in some cases, parenteral exposure from DEHP in medical devices, such as blood bags. It is unclear if DEHP absorbed from these different routes is equivalent in carcinogenicity. Certainly, although DEHP will be absorbed from blood bags intact, the action of nonspecific lipases in the gut results in absorption of the hydrolysis products 2-EH and MEHP rather than DEHP itself. For the purpose of this risk assessment, however, we will assume that DEHP absorbed by all routes is equivalent.
In addition to differences in routes of exposure, human exposure to DEHP differs from that of the rodents in the NTP bioassay in its temporal pattern; humans are not exposed to DEHP at a constant dietary concentration for their lifetime starting shortly after weaning. The actual temporal pattern has not been evaluated in detail, but it is likely to be nonuniform. Infants may be exposed to higher than average amounts of DEHP as a result of chewing and sucking PVC teethers, pacifiers, and toys and from skin contact with vinyl playpen liners, baby pants, and so on.(107) Individuals receiving multiple transfusions of blood or blood products (e.g., hemophiliacs) are also likely to be exposed to higher than average levels of DEHP, since the plasticizer is known to leach from the PVC blood bags into the blood during storage. (l18. 119) It is common practice in conducting carcinogenic risk assessments to equate risks in humans and animals receiving the same average lifetime daily dose (mg/kg per day). However, if the multistage model of carcinogenesis is correct, Day and Brown(lo8) have demonstrated that for any particular tcmporal pattern of exposure, the lifetime risk of cancer will depend on whether the carcinogen is an e,arly stage carcinogen (an initiator) or a late stage carcinogen (a promoter).
Unfortunately, we do not know at what stage or stages DEHP acts to produce carcinogenic effects. There is some indirect evidence that it may be a promoter. Reddy and Rao(lZ0) have shown that the hypolipidemic drugs Wy-16,634 and clofibrate promote the appearance of hepatocellular carcinoma in the liver of rats given an initiating dose of the liver carcinogen diethylnitrosamine (DEN).
As discussed earlier, these drugs produce a similar spectrum of effects in the liver of rodents as does DEHP. Hence, DEHP may also be a promoter. Additional support for this hypothesis comes from the work of Ward et al., (lZ1) who found an increase in preneoplastic foci and adenomas in the liver in mice given an initiating dose of DEN followed by treatment with DEHP compared to those receiving DEN without DEHP. However, this effect has not been confirmed by others. ( l Z 2 ) As discussed earher, Hirota and Yokoyama(88) and Ito et al. (89) have reported data suggesting that hydrogen peroxide is a tumor promoter in the gut. However, Levin et al.(9a) have reported that hydrogen peroxide is mutagenic in a specially constructed tester strain of Salmonella, and if the mechanism of aotion proposed earlier involving peroxisome proliferation is correct, the DNA damage that would be caused hy the active oxygen species generated by the peroxisomes might initiate tumor development. (99) It is possible that DEHP has both initiating and promoting activity.
Since we do not know whether DEHP acts as an initiator, a promoter, or both, we will use the simple assumption that risk is a function of lifetime average daily dose.
Interspecies differences in target-site susceptibility
The liver in rodents appears to be particularly susceptible to the induction of tumors, as evidenced by the high and variable incidence of spontaneous liver tumors in various strains of the high spontaneous incidence in the livers of rats of preneoplastic cells that can be stimulated by promoting agents to produce tumors, (17-19) and the high proportion of animal carcinogens whose site of action is the rodent liver. (123) By contrast, few chemicals are known to cause liver tumors in humans,(z0) and humans seem to be less susceptible to peroxisome proliferation than are rats.('*' Hence, if the peroxisome proliferation hypothesis of carcinogenesis is correct, humans would be expected to be less susceptible than rodents. Unfortunately, no data are available that would allow this (difference in sensitivity to be taken into consideration in a quantitative way. We are limited to noting (qualitatively that this is another reason why use of the available animal data is likely to result in overestimation of the risk to humans of DEHP.
Interspecies differences in metabolism
Albro and co-workers have conducted and reported on numerous studies of the metabolism of DEHP in various species of rodents, the Green monkey, and man. Data available from studies in various species are summarized in Table 9 ,(47) which reveals striking differences in the pattern of urinary metabolites between man and rat and the similarity between man and monkey. Another difference between the rat and man is that the major fraction of metabolites formed in man and the green monkey is excreted in conjugated form, whereas little such conjugation takes place in the rat. (47) Albro et aLC4') have suggested that rats compensate for not making glucuronides by carrying oxi- dative metabolism all the way to the highly water-soluble diacids. These authors also noted that if formation of hydroxyl side chains involves by analogy with fatty acid w-oxidation, a mixed function oxidase reaction, one would expect a net conversion of NAD(P)H to NAD(P). The additional steps from alcohol to aldehyde (or ketone) and from aldehyde to acid, as well as the apparent a-and p-oxidations needed to produce metabolites I, 11, and 111, would all be associated with net conversion of NAD(P) to NAD(P)H. Thus, the overall demand on the oxidation potential of the liver when high doses of DEHP are given would be in opposite directions for rat and primate. Albro et al. (47) concluded that to the extent that metabolism of DEHP is involved in its biological activity, one must question seriously whether rats are an appropriate model for man.
Although the metabolic differences between man and rats are striking, the differences are not so marked when one compares mouse and man (Table 9 ). Because the NTP bioassay revealed that DEHP is carcinogenic in mice, it may appear that metabolic differences are not important for carcinogenesis. However, Table 9 shows that rats and mice produce similar percentages of metabolite I, and both differ from humans. If metabolite I is an indicator of peroxisome proliferation and enhanced ,%oxidation as has been hypothesized, then in keeping with the hypothesis relating peroxisome proliferation to hepatic tumors, the major differences between rodents and primates in metabolite I production imply equally major differences in susceptibility to cancer from DEHP.
As with all the other data we have described, there are gaps and uncertainties in the metabolism data. Most important is the fact that the data shown in Table 9 were obtained under different experimental conditions for the different animal species and are therefore not strictly comparable. To address this uncertainty, a study has been conducted to compare the metabolic fate of DEHP when administered under identical conditions to monkeys, rats, and mice. (94) In this comparative metabolism study, a single dose (100 mg/kg) of 14C-labeled DEHP in corn oil was administered by gastric intubation to 3 male cynomolgous monkeys, 5 male F-344 rats, and 25 male B6C3F1 mice. All 3 species excreted an average of 30-40% of the dose in the urine, all but 5% or less in the first 12 hours after dosing in the mouse and rat and in the first 24 hours in the monkey. All species excreted about 50% of the dose in the feces, all but 3 % or less during the first 24 hours in the mouse and rat and during the first 48 hours in the monkey.
The metabolites excreted in the urine were identified as shown in Table 10 . In general, the pattern Albro. bThe mouse urine extract analyzed by HPLC contained only 79% of the radioactivity excreted in 0-24 hours. The remainder of the radioactivity was eluted from the SAC-2 resin in the acidic aqueous wash and probably contained some of the more polar metabolites, perhaps including glucuronides.
CRadioactivity in the sample was less than twice background for the system. dThis fraction may include metabolite VIII, which was identified in monkey urine after IV administration of DEHP.'9z1 of urinary metabolites identified in this study is similar to that described by Albro et al.(47) in rats, mice, and monkeys. In particular, metabolite I constitutes a high proportion of the total urinary metabolites in the mouse (13%) and the rat (11%) but only a very low proportion of the total urinary metabolites in the monkey (0.5%). If the hypothesis described earlier regarding the mechanism of carcinogenicity of DEHP is correct, and production of metabolite I is an indicator of target-site dose, the carcinogenicity of DEHP in monkeys (and presumably in humans, who also excrete very small amounts of metabolite I) is likely to be much lower than in rats or mice at the same dose level. Since it is not known what proportion, if any, of the metabolite I produced in monkeys is formed by &oxidation in the peroxisomes, and hence would produce peroxide, it is not possible to quantify the likely difference in susceptibility to DEHP-induced carcinogenicity between monkeys and rodents. However, if comparative urinary excretion of metabolite I can be used as an indicator, monkeys would be 20-to 25-fold less susceptible than rodents (Table 10 ).
If the metabolic and biological data are keys to carcinogenic activity, they strongly suggest that risk predicted under all of our various models simply does not apply to man or, more likely, that the magnitude of human risk is, at a given (low) level of exposure, very much less than that predicted for rodents. Although direct evidence supporting this assumption is lacking, it is supported by the currently most reasonable hypothesis about the tumorigenic action of peroxisome proliferators in rodents. The actual human risk per unit of exposure cannot be quantified but is likely to be less than that predicted for rodents and may even be zero.
In performing rodent to human extrapolation for this risk assessment we have used 2 procedures, both of which probably overestimate the risk to humans. Both assume that humans are at equal risk as rodents at the same dose level in mg/kg per day.(105) The first, and most conservative, procedure assumes that the relevant dose level is the applied dose of DEHP and, thus, takes into account none of the information available on the likely mechanism of action of DEHP in rodents and the data suggesting that the effects seen in rodents are not likely to occur in monkeys or humans.
The second procedure uses the dose adjustment discussed in thle previous section. This adjustment uses the relationship between applied dose of DEHP and urinary excretion of metabolite I in rats as a surrogate for the likely target-site dose of active oxygen species ,generated by the peroxisomes. This second procedure assumes the same relationship in rats and in humans between the applied dose of DEHP and the dose of metabolite 1, the latter being a surrogate for the dose of the ultimate carcinogen. The dose of metabolite I at low doses of DEHP is calculated using the relationship determined empirically in rats from data generated by Robinson et al.(57) :
where I = dose of metabolite I, and D = daily dose of DEHP.
Under these assumptions, the data presented in Tables 6 and 7 imay be applied directly to humans to estimate the risk at low dose levels predicted by application of the multistage model without ( Table 7) the surrogate target-site dose adjustment described above. Similarly, Table 8 shows the virtually safe doses predicted by the Mantel-Bryan model without and with the same adjustment.
NOEL/Safety factor approach to risk assessment
If the mechanism of carcinogenicity of DEHP that has been proposed above is correct, no increased risk of cancer would occur at exposure levels that do not cause peroxisome proliferation and subsequent excess peroxide production. Such pathological effects are of the type normally protected against by the classic toxicological procedure of identification of a no-observed-effect level (NOEL) and application of a safety factor to determine an acceptable daily intake (ADI). To use this procedure, it is of course necessary to identify a NOEL. Unfortunately, it is not clear if a NOEL has been identified. In the Phase I validation study of the CMA Voluntary TSCA testing program,(I4) groups of 12 male and 12 female F-344 rats were fed diets containing DE,HP at 0, 1000, 6000, and 12,000 ppm for 3 weeks. The activity of the enzyme carnitine acetyltransferase, which occurs in the peroxisomes and the mitochondria, showed a dose-related increase in activity at all dose levels after as little as 1 week of treatment. Dose-related effects were also noted on liver weight (increased 20, 66, and 98% in male rats at 3 weeks), serum triglycerides (decreased to 56, 31, and 18% of control in males at 3 weeks), and a cytochemical test (dose-related increase in peroxisome proliferation). Males were affected more than females. These effects were not evident, however, in the animals allowed 2 weeks of recovery after DEHP treatment, indicating that the effects are reversible.
The European Chemical Industry Trade Association (CEFIC) sponsored a similar study in which groups of male and female Alderly Park SPF-derived albino rats, (number unspecified) were fed DEHP at 0, 50,200, and 1000 mg/kg per day (about 1000 ppm, 4000 ppm, and 20,000 ppm) for 28
Liver weight was increased in all treated groups in a dose-related manner. There was a dose-related proliferation of peroxisomes starting at the lowest dose level and a similar proliferation of smooth endoplasmic reticulum.
Morton'80) fed DEHP at various dose levels to groups of 5-12 male Sprague-Dawley rats for 7 days and measured such parameters as liver weight, serum triglyceride level, liver catalase, carnitine acetyltransferase (CAT), carnitine palmitoyltransferase (CPT), and (3-oxidation activity. Liver weight was significantly increased in a dose-related manner at DEHP dietary levels of 1000, 2500, and 5000 ppm but not at 50, 100, or 500 ppm. Serum triglyceride levels were significantly reduced in a dose-related manner at all levels tested (50, 500, and 2500 ppm). Catalase activity was increased significantly at 5000 ppm but not at 100 or lo00 ppm. CAT and CPT activities were significantly increased in a dose-related manner at 100, 500, 1000, and 2500 ppm but not at 50 ppm.
Of perhaps most importance to the present discussion is the liver 0-oxidation activity. When total liver 6-oxidation activity was measured, significant dose-related increases were seen at 500, 1000, and 5000 ppm, and slight but not significant increases were seen at 50 and 100 ppm. Morton(801 also exaimined 0-oxidation activity in isolated mitochrondria and peroxisomes after feeding DEHP, at 0, 100, 1000, and 5000 ppm. In peroxisomes, @-oxidation activity was increased significantly only at 5000 ppm, but slight, nonsignificant increases were seen at 100 and lo00 ppm. In isolated mitochondria, &oxidation activity was increased significantly at 5000 and 1000 ppm and slightly but not significantly at 100 ppm.
In a study recently conducted by the British Industrial Biological Research Association, (Iz5) DEHP was fed to groups of 5 Fischer 344 rats of each sex at dietary levels of 0, 100, 1000, 6000, 12,000, and 25,000 ppm for 21 days. Males and females fed 6000 ppm or more showed significantly increased liver weights and significantly increased peroxisomal 0-oxidation activity. Serum triglyceride levels were significantly reduced at the same levels in males. Microsomal lauric acid 11-and 12hydroxylase activity was significantly increased in males at lo00 ppm and above, as was the number of peroxisomes in the liver. These latter effects were seen in females only at 6OOO ppm or more. No significant changes in any of the parameters monitored occurred at 100 ppm, with the exception of an increase in serum triglyceride level in males.
In attempting to identify a NOEL from these data, several choices are possible. Based on the dose level causing a significant increase in peroxisomal &oxidation activity in the studies by Morton(80) and BIBRA,('*') a NOEL of lo00 ppm could be identified (about 70 mg/kg per day based on Morton's food consumption and body weight data or 106 mg/kg per day based on BIBRA data). Based on total liver P-oxidation activity, the NOEL would be set lower, at 100 ppm (about 7 mg/kg per day). A NOEL for all effects of 100 ppm (about 11 mg/kg per day) was identified in the BIBRA study.(125) However, a NOEL for all effects cannot be identified from the Morton study,(so) since a significant reduction in serum triglyceride level was seen even at the lowest dose of 50 ppm (about 3.5 mg/kg per day), though such an effect was not seen in the BIBRA study at levels below 6OOO ppm. Since these possible NOELS are derived from studies of short-term exposure (7-21 days), estimation of a chronic AD1 for humans would typically involve application of a safety factor of loOO.(lll) This would lead to a chronic AD1 of between 70 to less than 3.5 pg/kg per day, with the most likely value being 11 pg/kg per day, which is derived from the NOEL for peroxisomal proliferation in the BIBRA study. ('25) 
DISCUSSION
To provide a comparison of the implications for risk at low dose levels of these 5 models (multistage and Mantel-Bryan models, both with and without target-site dose adjustment, plus threshold model) their predictions of virtually safe dose (risk less than 10+ on lifetime exposure) or AD1 are listed in Table 11 . For the multistage model, both maximum likelihood estimates and 95th percentile upper confidence estimates are listed. For each model, results for the data set (species and sex) predicting the highest risk are presented.
Under the most conservative procedure (upper confidence limit on multistage model with applied dose levels), exposure would need to be less than 1.5 pg/kg per day to ensure a lifetime risk of less than 1 in 1 million At the other extreme, the Mantel-Bryan model using the surrogate targetsite dose adjustment predicts a risk of less than at a daily dose of 791 pg/kg per day. The model that is most consistent with our general understanding of cancer development (the multistage model) when combined with our attempt to make the best use of data to provide inferences regarding the likely shape of the dose-response curve at low doses (the surrogate target site dose adjustment) predicts a lifetime risk of These estimates of "virtually safe dose" assume equal risk to humans and rodents at the same dose or less at DEHP dose levels as high as 116 pg/kg per day. Mantel-Bryan with applied 11.9
Mantel-Bryan with surrogate 79 1
Threshold
53.5-70
=The safe dose levels listed represent the dose levels associated with a lifetime risk of or less predicted by the multistage or Mantel-Bryan model or the AD1 predicted by application of a safety factor to the NOEL as described in the text?. In each case, the value for the species and sex predicting the lowest safe level (highest risk) is listed. level of DEHP. However, as we have discussed above, there is information on interspecies differences in target organ susceptibility and in physiological and biochemical responses to DEHP that suggest that humans are likely to be less susceptible to the carcinogenic effects of DEHP than rodents. That is, all of the estimates in Table 11 probably overestimate the risk to humans from DEHP exposure.
In conclusion, there is a substantial body of data tb indicate that the simple application of a low dose extrapolation model to the available data on the carcinogenicity of DEHP to estimate human risks likely overestimates these risks. Factors contributing to such overestimation are (1) the likely mechanism of carcinogenicity of DEHP in rodents and the likely nonlinear relationship between the administered dose of DEHP and the dose of the proximate carcinogenic species, (2) differences in target-site sensitivity between humans and rodents for liver tumors in general, and (3) differences in the response of monkeys and probably humans to DEHP, which indicate that the hypothesized mechanism of carcinogenicity of DEHP in rodents does not occur or occurs to a lesser extent in humans than in rodents.
